BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients. These results are being presented at the 2009 San Antonio Breast Cancer Symposium (SABCS). The complete poster (#5111) entitled, “A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 - an Oral Inhibitor of ErbB2,” is available as a PDF on Array's website at www.arraybiopharma.com.
